Tag Archive for: board of directors

Mestag Therapeutics Appoints Philip Astley-Sparke and Victor Sandor, M.D.C.M., to its Board of Directors

/in

— Mr. Astley-Sparke brings more than two decades of biotech leadership, having scaled several highly innovative transatlantic companies, including Replimune, uniQure and BioVex — Dr. Sandor brings more than 20 years of oncology clinical development experience, including leading programs to regulatory approval at Array BioPharma, Incyte and AstraZeneca — Appointments strengthen the Board as Mestag evaluates […]

Read more

Hansa Biopharma Announces New Board Appointments

/in

Lund, Sweden, September 24, 2026. Hansa Biopharma AB (publ), “Hansa” (Nasdaq Stockholm: HNSA), announced today the election of Shannon Campbell and Gregory Perry to Hansa’s Board of Directors, effective September 22, 2026 until the end of the next Annual General Meeting. Read more…

Read more

ViCentra Appoints Ian Wells as Chief Financial Officer and Adds Medtech Veteran Tom West to its Board

/in

Ian Wells, former Global Chief Financial Officer of HOYA Vision Care, appointed CFO, bringing multi-billion-dollar P&L leadership and capital-markets discipline Tom West, who led Intersect ENT to its $1.1 billion acquisition by Medtronic and Nalu Medical to its $600 million acquisition by Boston Scientific, joins as an Independent Board Member Appointments build the financial and […]

Read more

Ona Therapeutics Raises $86.6 Million Series B to Advance First-in-Class ADCs into Clinical Development

/in

Oversubscribed Series B financing co-led by new investors Columbus Venture Partners and Mérieux Equity Partners, with participation from additional investors COFIDES and Korys, alongside all existing investors Proceeds to support clinical development of lead first-in-class program ONA-255 in breast cancer, toward clinical proof of concept, and advance ONA-389 in colorectal cancer Financing supports Ona’s transition […]

Read more

Link Biologics strengthens Board with drug discovery expert Dr Niall Martin to advance its TSG-6-based therapeutic pipeline

/in

Dr Martin brings over two decades of leadership in translational science, drug discovery and biotech strategy and entrepreneurship Strengthens Link’s position as it advances its proprietary TSG-6-based therapeutic pipeline towards the clinic  London, UK – 24 February 2026 – Link Biologics (“Link” or “the Company”), the biotech company developing first-in-class TSG-6-based therapies, that have a unique […]

Read more
© Optimum Strategic Communications.